Challenges in Multivalvular Heart Disease: Indian Scenario

Suruchi Ladha¹  Poonam Malhotra Kapoor²

¹Department of Cardiac Anaesthesia, Cardio Thoracic Centre, All India Institute of Medical Sciences, New Delhi, India
Address for correspondence Poonam Malhotra Kapoor, Department of Cardiac Anaesthesia, Cardio Thoracic Centre, All India Institute of Medical Sciences, New Delhi, India (e-mail: drpoonamaiims@gmail.com).

Abstract

Multivalvular disease (MVD) is a common scenario with various clinical challenges and limited availability of evidence-based recommendations. The pathophysiology of patients having MVD is dependent on the specific combination of valve lesions. The anesthesiologist should be aware of the echocardiographic pitfalls as many commonly used echocardiographic parameters for the assessment and quantification of valve lesions is validated only in patients with single-valve disease. It is also necessary to take into account the interaction between the different valve lesions while interpreting echocardiography. The management decisions of such patients depend on the assessment of the different valve lesions and their effect on symptoms, pulmonary hypertension, and left ventricular dysfunction. The decision to intervene on multiple valves should take into account both the surgical risk of combined procedures and the advantages of available percutaneous techniques. In this review, we discuss the common clinical scenario, pathophysiology, echocardiographic challenges, and guideline-directed management options in patients with MVD.

Keywords
► multivalvular disease
► echocardiographic challenges and Indian scenario

Introduction

In the Indian subcontinent, patients having multivalvular disease (MVD) continue to be a frequent entity whose evaluation and management are challenging. MVD is the combination of stenosis or regurgitation, or both, on two or more valves of the heart.¹ There are a large number of possible combinations in patients with MVD, and this heterogeneity leads to availability of limited data.²,³ The European Society of Cardiology (ESC) guidelines in 2012 stated that there is a lack of data on mixed and multiple valvular heart disease, and this does not allow for evidence-based recommendations.² Although each case of MVD is different, in this review we consider the general pathophysiologic principles, assess the clinical and echocardiographic challenges to the anesthesiologist in MVD, and the potential management strategies.

Incidence and Etiology

In developing countries, rheumatic heart disease (RHD) continues to be the main etiology, whereas degenerative etiologies are increasing in developed countries.¹,⁴ In 2011, the Society of Thoracic Surgeons (STS) reported 10.9% of the patients undergoing valve surgery to have multiple-valve intervention in North America.⁵ In the Euro Heart Survey conducted in 2001 in 25 countries, 20.2% of the patients with native valve disease and 14.6% of the patients undergoing valvular surgery had MVD.⁶ In this survey, RHD was found to be the most frequent etiology (51.4%) of MVD, followed by degenerative valve disease (40.6%).⁶ The other causes of primary MVD include endocarditis, thoracic and mediastinal radiation therapy, end-stage renal disease, carcinoid heart disease, adverse effects of drugs, etc. Patients with Marfan’s syndrome, Ehlers-Danlos syndrome, trisomy 18, 13, and 15, etc., can also present with MVD.³
Pathophysiology

The natural history of MVD is determined by the relative severity of each individual lesion and the chronology and the chronicity of development. In such patients, the manifestation of proximal valve disease can obscure the manifestation of distal valve lesion. In addition, the consequences of various combinations of diseased valves on left ventricular (LV) and right ventricular (RV) geometry and function are generally different from the remodeling because of single-valve disease.

Echocardiographic Pitfalls in Evaluation of Multivalvular Disease

Echocardiography is one of the mainstays in the evaluation of patients with valvular heart disease. However, several commonly used echocardiographic parameters have been validated only in patients with single-valve disease and may not be valid in the setting of MVD. Measurements less dependent on loading conditions such as direct planimetry, the effective regurgitant orifice (ERO), vena contracta, etc., are preferred. There is a need to combine different measurements for complete evaluation as hemodynamic interactions between valve lesions can affect various measurements. The AHA/ACC (American Heart Association/American College of Cardiology) 2014 guidelines recommend that patients with mixed valve disease may require serial evaluations at intervals earlier than recommended for single-valve lesion.

Aortic Stenosis and Mitral Regurgitation

Clinical Scenario

Unger et al reported that some degree of mitral regurgitation (MR) is found in as many as 61 to 90% of patients undergoing aortic valve replacement (AVR) for aortic stenosis (AS). There can be three clinically common scenarios when an anesthesiologist can encounter this situation. The etiology of MR in patients with AS is often functional rather than anatomical. First, LV adverse remodeling due to AS can result in MR. Patients with AS develop LV dilatation and systolic dysfunction as a result of LV afterload mismatch, concomitant cardiomyopathy, or both. In turn, there is secondary MR due to mitral annular dilatation and leaflet tethering. Second, elderly patients with AS can have secondary MR. The risk factors for AS have been shown to be similar to those for atherosclerosis and coronary artery disease (CAD), so patients having significant CAD can present with severe AS and secondary ischemic MR. Third, patients with AS can have concomitant primary MR. Severe AS in association with significant MR is, however, one of the least common combinations of valvular lesions in RHD.

Pathophysiology

In patients having AS, the severity of MR increases with time because of several mechanisms, such as increase in the LV to left atrial (LA) pressure gradient, leading to increase in the regurgitant volume for any given ERO area. LV remodeling that may promote MV deformation, etc. MR contributes to a low-flow state in patients with AS. The presence of MR, whether primary or secondary, can alter the clinical presentation of patients with AS.

Echocardiographic Pitfalls

As described in pathophysiology, the systolic transmitral pressure gradient is increased due to AS, and hence, the echocardiographic measurements of regurgitant flow and the regurgitant volume will be increased for any given mitral regurgitant orifice area. There will be an increased area of mitral regurgitant jet using color-flow Doppler. In patients having secondary MR, the AHA/ACC 2014 guidelines recommend that the measurement of the proximal isovelocity surface area by two-dimensional (2D) echocardiography underestimates the true ERO because of the crescentic shape of the proximal convergence. The presence of MR, on the contrary, will lead to low flow, low gradient across the aortic valve.

Guideline-Directed Management

Table 1 highlights the salient features of the management of such combinations of valve lesions. The decision making in such patients include choosing from options such as double-valve replacement, AVR plus mitral valve repair, isolated AVR or transcatheter aortic valve implantation (TAVI) for patients deemed at the highest surgical risk. When MR is severe, double-valve surgery is generally done. However, even in this situation, some regression may occur even if the mitral valve is not operated. The prevalence of moderate or severe MR in patients who undergo TAVI for severe AS ranges between 19 and 30%. Prediction of improvement in MR after TAVI remains challenging. Limited evidence on the combined use of TAVI and MitraClip (Abbott Vascular, Santa Clara, California, United States) suggests that the combination is possible but with limited efficacy.

Aortic Stenosis and Mitral Stenosis

Clinical Scenario

In the Indian subcontinent, significant stenosis at multiple valves is usually due to RHD. Patients with degenerating AS can have progressive mitral annular calcification leading to degenerating mitral valve stenosis. Other causes include Shone’s complex, mucopolysaccharidosis, etc.

Pathophysiology

The clinical signs of upstream lesion that is mitral stenosis (MS) usually prevails. If atrial fibrillation develops in such a scenario, it is poorly tolerated by the patient.

Echocardiographic Pitfalls

The severity of MS is usually not affected by the presence of AS, but the gradients across the aortic valve may be reduced, resulting in low-flow, low-gradient AS and potential underestimation of AS severity. LV abnormal relaxation resulting from AS will increase the mitral E-wave pressure half-time. The pressure half-time method used to estimate the severity of MS is unreliable in the presence of AS. Planimetry continues to be the standard method to assess mitral area, but heavy calcifications can impair its measurement also.
**Table 1** The American and European guidelines for various combinations of aortic stenosis and mitral regurgitation

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Severe AS and severe MR</td>
<td>AVR is indicated for patients with severe AS (stage C or D) when undergoing other cardiac surgery. (COR I, LOE C)</td>
<td>AVR is indicated in patients with severe AS undergoing surgery on another valve (COR I, LOE C)</td>
</tr>
<tr>
<td></td>
<td>Concomitant MV repair or replacement is indicated in patients with chronic severe primary MR undergoing cardiac surgery for other indications (COR I, LOE B)</td>
<td>It is recommended that severe chronic functional MR should be corrected at the time of bypass surgery (COR I, LOE C)</td>
</tr>
<tr>
<td></td>
<td>MV surgery is reasonable for patients with chronic severe secondary MR (stages C and D) who are undergoing AVR (COR IIA, LOE C)</td>
<td>In secondary MR, because of their prognostic value, lower thresholds of severity, using quantitative methods, have been proposed (20 mm² for EROA and 30 mL for regurgitant volume)</td>
</tr>
<tr>
<td>Severe AS and moderate MR</td>
<td>Concomitant MV repair is reasonable in patients with chronic moderate primary MR (stage B) undergoing cardiac surgery for other indications (COR IIA, LOE C)</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>MV repair may be considered for patients with chronic moderate secondary MR (stage B) who are undergoing other cardiac surgery (COR IIB, LOE C)</td>
<td></td>
</tr>
<tr>
<td>Severe MR and moderate AS</td>
<td>AVR is reasonable for patients with moderate AS (stage B) (aortic velocity 3.0–3.9 m/s) who are undergoing other cardiac surgery (COR IIA, LOE C)</td>
<td>AVR should be considered in patients with moderate AS undergoing surgery on another valve (class IIA, LOE C)</td>
</tr>
</tbody>
</table>

**Guideline-Directed Management**

The salient features of management in such scenario is described in Table 2. The AHA/ACC guidelines mainly refer to rheumatic mitral valve disease, and the approach to degenerative mitral valve disease may differ. In patients with severe AS undergoing TAVI, the concomitant MS is generally of degenerative etiology, and usually, there is no commissural fusion, and is therefore not suitable for percutaneous mitral commissurotomy.

**Aortic Regurgitation and Mitral Stenosis**

**Clinical Scenario**

Combined aortic regurgitation (AR) and MS in the adult age group usually reflect the natural progression of valve lesions following rheumatic fever in the Indian scenario.

**Pathophysiology**

In isolated MS, LV preload and diastolic pressure are reduced as a function of the severity of inflow obstruction. However, because of AR, the diastolic pressure may rise depending on the compliance. The combination of aortic regurgitation and MS results in opposite loading conditions on the LV. As the cardiac output falls with progressive degrees of MS, trans-aortic valve flows will decline, masking the potential severity of the aortic valve lesion, and hence, the clinical signs such as increased pulse pressure might not be observed.

**Echocardiographic Pitfall**

AR shortens directly measured pressure half-time proportional to the regurgitant fraction, but an increase in left ventricular compliance could offset this effect. This shortening of pressure half-time leads to mitral valve area over-

**Guideline-Directed Management**

The guideline for managing this combination is mentioned in Table 2.

**Aortic Regurgitation and Mitral Regurgitation**

**Clinical Scenario**

Significant regurgitation at multiple valves is usually non-rheumatic; however, in the Indian subcontinent patients with RHD can also have similar presentation. Patients with Marfan’s syndrome may have both AR from aortic root dilatation and MR due to mitral valve prolapse. Myxomatous degeneration causing prolapse of multiple valves (mitral, aortic) can also occur in the absence of an identifiable connective tissue disorder. This condition can also be caused by primary AR and concomitant functional MR due to left ventricular enlargement, but lesions can also be primary in both valves, as in endocarditis, carcinoid disease, etc. The prevalence of secondary MR in patients with AR varies from 6 to 45%.

**Pathophysiology**

This condition, characterized by severe volume overload caused by the two regurgitations, is usually poorly tolerated and results in early heart failure. Symptomatic patients with this combination of valve lesions have decreased LV function than those with isolated AR or MR, resulting in postoperative LV dysfunction.
Table 2 The American and European guidelines for various combinations of mitral and aortic stenosis

<table>
<thead>
<tr>
<th>Combination</th>
<th>AHA/ACC guidelines (2014)</th>
<th>ESC guidelines (2012)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Severe MS and severe AS</td>
<td>Concomitant MV surgery is indicated for patients with severe MS (MVA &lt; 1.5 cm², stage C or D) undergoing other cardiac surgery. (COR I, LOE C)</td>
<td>Severe concomitant aortic valve disease is a contraindication for PTMC. In patients with severe MS combined with severe aortic valve disease, surgery is preferable. AVR is indicated in patients with severe AS undergoing surgery of another valve (COR I, LOE C)</td>
</tr>
<tr>
<td>Severe MS and moderate AS</td>
<td>AVR is reasonable for patients with moderate AS (stage B) (aortic velocity 3.0–3.9 m/s) who are undergoing other cardiac surgery (COR IIa, LOE C)</td>
<td>In patients with severe MS and moderate aortic valve disease, PMC can be performed as a means of postponing the surgical treatment of both valves</td>
</tr>
<tr>
<td>Severe AS and moderate MS</td>
<td>Concomitant mitral valve surgery may be considered for patients with moderate MS (MVA 1.6–2.0 cm²) undergoing other cardiac surgery (COR IIB, LOE C)</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: AHA/ACC, American Heart Association/American College of Cardiology; AS, aortic stenosis; AVR, aortic valve replacement; COR, class of recommendation; ESC, European Society of Cardiology; LOE, level of evidence; MV, mitral valve. MVA, mitral valve area; PMC, percutaneous mitral commissurotomy; PMTC, percutaneous transvenous mitral commissurotomy.

Echocardiographic Pitfall
The use of Doppler volumetric method is not validated.1

Guideline-Directed Management
In treating combined AR and MR, the incomplete reversibility of left ventricular dilatation due to AR should be kept in mind. If indications for AVR are fulfilled, concomitant mitral valve repair should be considered. ESC 2012 guideline states that If AR requiring surgery is associated with severe MR, both should be operated on.2

Mixed Aortic Valve Disease
There is paucity of data about the natural history of combined AS and AR, making evidence-based recommendations regarding AVR challenging.22 In clinical practice, the management of patients with combined aortic valve disease usually follows the recommendations of the predominant lesion.2 The current indications for surgery have been defined for single-valve disease and are "extrapolated" to patients with mixed-valve disease. The peak aortic velocity is a reliable prognostic indicator for isolated AS,23 but in combined disease, it is likely to overestimate the severity of stenosis because of increased stroke volume. This increased velocity will also lead to increased LV aortic Doppler-derived pressure gradient to values higher than expected for the true systolic valve orifice size as measured by planimetry. The pressure half-time used for evaluating AR may be prolonged when left ventricular hypertrophy with impaired relaxation is present due to AS. Thus the

Table 3 The American and European guidelines for various combinations of mitral stenosis and aortic regurgitation

<table>
<thead>
<tr>
<th>Combination</th>
<th>AHA/ACC guidelines (2014)</th>
<th>ESC guidelines (2012)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Severe AR and severe MS</td>
<td>AVR is indicated for patients with severe aortic regurgitation (stage C or D) undergoing cardiac surgery for other indications (COR I, LOE C)</td>
<td>Surgery is indicated in patients with severe aortic regurgitation undergoing surgery on another valve (COR I, LOE C)</td>
</tr>
<tr>
<td>Severe MS and moderate AR</td>
<td>AVR is reasonable for patients with moderate aortic regurgitation undergoing other cardiac surgery (COR IIa, LOE C) MV surgery is reasonable for severely symptomatic patients (NYHA class III/IV) with severe MS (MVA 1.5 cm², stage D), provided there are other operative indications (aortic valve disease) (COR IIa, LOE C)</td>
<td>In patients with moderate AR, who undergo MV surgery, the decision to treat the aortic valve should be based on the etiology of the AR, age, worsening of LV function, and the possibility of valve repair.</td>
</tr>
<tr>
<td>Severe AR and moderate MS</td>
<td>Concomitant MV surgery may be considered for patients with moderate MS (MVA 1.6–2.0 cm²) undergoing other cardiac surgery (COR IIB, LOE C)</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: AHA/ACC, American Heart Association/American College of Cardiology; AR, aortic regurgitation; AVR, aortic valve replacement; COR, class of recommendation; ESC, European Society of Cardiology; LOE, level of evidence; LV, left ventricular; MV, mitral valve. MVA, mitral valve area; NYHA, New York Heart Association.
Challenges in Multivalvular Heart Disease

Table 4 The American and European guidelines for treatment of TR

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary TR</td>
<td>COR</td>
<td>LOE</td>
</tr>
<tr>
<td>Severe TR undergoing left-sided surgery</td>
<td>I Not specified</td>
<td>C</td>
</tr>
<tr>
<td>Moderate TR undergoing left-sided surgery</td>
<td>I</td>
<td>C</td>
</tr>
<tr>
<td>Secondary TR</td>
<td>Ila (with RV dilatation or prior right-sided heart failure)</td>
<td>B</td>
</tr>
<tr>
<td>Severe TR undergoing left-sided surgery</td>
<td>IIb</td>
<td>C</td>
</tr>
<tr>
<td>Mild or moderate TR with dilated annulus (&gt;40 mm or 21 mm/m²) undergoing left-sided surgery</td>
<td>IIb</td>
<td>C</td>
</tr>
</tbody>
</table>

Abbreviations: AHA/ACC, American Heart Association/American College of Cardiology; COR, class of recommendation; ESC, European Society of Cardiology; LOE, level of evidence; PH, pulmonary hypertension; RV, right ventricular; TR, tricuspid regurgitation.

quantification of the severity of combined aortic valve disease is complex as the measures of severity are affected by the coexisting lesion. Aortic valve area may not provide required information as it reflects the severity of AS only, and not accounting for the severity of AR.

Mixed Mitral Valve Disease

Similar to the aforementioned mixed aortic valve disease, in mixed mitral valve disease the peak mitral valve E-wave velocity may be increased. In the setting of severe MR because of enhanced early-diastolic flow, the peak mitral valve E-wave velocity may not accurately reflect the contribution to LA hypertension from any associated MS. When AR or MR is the dominant lesion in patients with mixed aortic or mitral valve disease, respectively, the LV is dilated. When AS or MS predominates, LV chamber size will be normal or small. Also, the presence of moderate or severe MR in patients with rheumatic MS is a contraindication to percutaneous mitral balloon valvotomy (PMBV).

Tricuspid Regurgitation and Left-Sided Valve Disease

Primary (or organic) TR is caused by congenital or acquired abnormalities of the TV. Secondary (or functional) TR occurs due to deformation of the TV apparatus. The majority of TR is secondary to conditions that cause RV and/or right atrial dilatation, including left-sided heart disease and chronic atrial fibrillation. Approximately 20 to 30% of patients undergoing cardiac surgery for left-sided valvular disease present with significant TR. Both ESC 2012 and ACC/AHA 2014 guidelines favor a more proactive approach to TR correction and highlight the shifting consensus toward a liberal approach to surgical correction (Table 4). There is a common consensus that severe TR should be treated in patients undergoing left-sided cardiac surgery. The guidelines strongly encourage the surgical correction of less than severe functional TR if the tricuspid annulus dilation is > 40 mm on TTE (> 21 mm/m²) or > 70 mm on direct intraoperative measurement in patients undergoing left-sided valve surgery.

Conclusion

The thorough understanding of the pathophysiology and the echocardiographic challenges will help in better management of the various situations arising from different combinations of the valve lesions in patients with MVD. It is important to understand both the diagnostic and therapeutic challenges in such clinical scenarios. The global consequences of all lesions should be considered before any decision making. The perioperative risk and benefits of double-valve surgical intervention should be considered on a case-by-case basis. The use of percutaneous intervention in patients with MVD is in its infancy, but the future development of transcatheter techniques will offer the possibility of staged procedures in high-risk patients.

References

11 Paradis JM, Fried J, Nazif T, et al. Aortic stenosis and coronary artery disease: what do we know? What don’t we know? A comprehensive review of the literature with proposed treatment algorithms. Eur Heart J 2014;35(31);2069–2082
20 van Karnebeek CD, Naeff MSJ, Mulder BJM, Hennekam RCM, Offringa M. Natural history of cardiovascular manifestations in Marfan syndrome. Arch Dis Child 2001;84(02);129–137